Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU
Bayer will start marketing the new oral, once-daily anticoagulant very soon / First-in-class product to demonstrate superior efficacy to current standard of care
02-Oct-2008 -
The Bayer Group has achieved a major success in its product development: The European Commission has granted marketing approval for Xarelto® (rivaroxaban), a novel anticoagulant taken as one tablet, once-daily, for the prevention of venous blood clots in adult patients undergoing elective ...
Acute Coronary Syndrome
atrial fibrillation
Bayer
+11